Novo Nordisk v. Mylan: Ozempic Semaglutide Patent Case Settled in 93 Days
Novo Nordisk A/S filed suit against Mylan NV in the District of Delaware, asserting two patents covering semaglutide injection formulations underpinning Ozempic. The parties reached a negotiated settlement and the action was dismissed without prejudice just 93 days after filing — an unusually swift resolution for pharmaceutical patent litigation of this profile.
Novo Nordisk’s Ozempic IP fortress tested — and quickly settled
On 1 July 2024, Novo Nordisk A/S filed a patent infringement action against Mylan NV in the U.S. District Court for the District of Delaware before Judge Colm F. Connolly, asserting patents US8129343B2 and US10335462B2 against Mylan’s proposed semaglutide injection product (2 mg/3 mL, 0.68 mg/mL) — a generic equivalent to Novo Nordisk’s blockbuster GLP-1 receptor agonist Ozempic, which is approved for type 2 diabetes management and widely associated with weight-loss treatment.
The action resolved on 2 October 2024 when both parties executed a Settlement Agreement and filed a Stipulation and Order of Dismissal without prejudice. All claims, counterclaims, affirmative defenses, and demands were dismissed without prejudice and without costs to either party. The court retained jurisdiction solely to enforce or supervise performance under the Settlement Agreement, suggesting ongoing contractual obligations — potentially including a negotiated entry date for Mylan’s generic — remain operative between the parties.
A 93-day resolution is striking for pharmaceutical patent litigation, which often runs years in Delaware. The speed suggests the parties likely entered settlement negotiations early and the commercial stakes — Ozempic’s multi-billion-dollar revenue — may have incentivised rapid deal-making. The specific terms of the Settlement Agreement, including any authorised generic launch date or licensing provisions, are not part of the public record, leaving the competitive implications for the semaglutide market only partially visible.
Filing to Dismissed without Prejudice in 93 days
93 days — notably faster than the median ANDA/pharma patent case in Delaware, which typically runs 2–3 years to trial
Dismissed without prejudice: what the settlement order means for both parties
Dismissal without prejudice preserves Novo Nordisk’s future options
A dismissal without prejudice means neither party obtained a merits adjudication. Critically, Novo Nordisk is not barred from re-filing the same patent claims against Mylan if the Settlement Agreement is breached or if Mylan’s commercial conduct changes. The court’s retained jurisdiction to enforce the Settlement Agreement confirms the parties’ ongoing obligations under private terms not disclosed in the public record.
No merits ruling — re-filing permittedNovo Nordisk avoids validity challenge — patents remain intact
By settling before any claim construction or validity ruling, Novo Nordisk preserved US8129343B2 and US10335462B2 in full force. No court has found either patent invalid or not infringed. This is significant: a contested Mylan defence could have produced invalidity or non-infringement rulings enforceable in subsequent ANDA litigations with other generic filers. Settlement forecloses that risk entirely, at least for now.
Patents intact, no adverse rulingMylan gains negotiated certainty — at an undisclosed price
Mylan avoids the litigation cost and uncertainty of a full Delaware bench trial on semaglutide formulation patents. The settlement likely includes a negotiated authorised launch date or licensing arrangement, which is standard in Hatch-Waxman settlements. However, the specific date and any royalty or exclusivity terms are confidential. Mylan’s ability to commercialise its semaglutide product depends entirely on those undisclosed terms.
Launch terms confidentialOzempic’s IP perimeter holds — for now — in the GLP-1 market
The settlement without prejudice, combined with no costs award, is consistent with a negotiated entry-date deal that Novo Nordisk has used with other generic challengers across its GLP-1 portfolio. For the broader semaglutide competitive landscape, this outcome suggests Novo Nordisk’s patent position was strong enough to deter a full challenge, or Mylan’s commercial calculus favoured a secured future entry date over an unpredictable litigation outcome worth billions in market exposure.
GLP-1 patent perimeter reinforcedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk A/S | Individual | Global biopharma — holder of US8129343B2 and US10335462B2 covering Ozempic (semaglutide)Search in Eureka ↗ |
| Co-Plaintiff | Novo Nordisk A/S | Individual | Search in Eureka ↗ |
| Defendant | Mylan, NV | Company | Mylan NV — global generic pharmaceutical manufacturer seeking semaglutide market entrySearch in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Travis J. Murray | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Novo Nordisk A/SSearch in Eureka ↗ |
| Defendant counsel | Brandon M. White | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | David L. Anstaett | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Shannon M. Bloodworth | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Stamatios Stamoulis | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Stamoulis & Weinblatt LLC | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Stipulation and Order of Dismissal reflects a fully negotiated resolution: all claims and counterclaims are extinguished without prejudice, with no admission of liability or finding on the merits of infringement, validity, or enforceability of either asserted patent. The explicit waiver of any right to appeal, combined with the court’s retained supervisory jurisdiction, indicates that the Settlement Agreement contains operative ongoing obligations — most likely a contractually agreed commercial launch date for Mylan’s semaglutide product. Neither patent was adjudicated, leaving Novo Nordisk’s IP position legally undiminished.
US8129343B2 & US10335462B2 — Semaglutide formulation patents for Ozempic
US8129343B2 (application US11/908834) and US10335462B2 (application US15/656042) collectively protect the semaglutide compound and formulation technology underlying Ozempic — Novo Nordisk’s GLP-1 receptor agonist approved for type 2 diabetes and, more recently, associated with significant weight-loss outcomes. Semaglutide is a fatty-acid acylated GLP-1 analogue designed for once-weekly subcutaneous dosing, and the asserted patents encompass both the molecular composition and specific pharmaceutical formulation parameters including the concentration ranges appearing in the accused Mylan product.
These patents sit at the core of one of the most commercially valuable pharmaceutical franchises in the world. Ozempic generated multi-billion-dollar annual revenues, and the asserted patent pair represents a dual-layered exclusivity barrier — compound-level and formulation-level — that any generic semaglutide entrant must design around or challenge. The fact that Mylan settled rather than litigating either patent to judgment reinforces their strategic weight. For any pharmaceutical company operating in the GLP-1 or incretin-based therapy space, these patents define the central clearance challenge for the coming years.
Should your team run an FTO analysis against US8129343B2 and US10335462B2?
Any pharmaceutical company developing or commercialising a GLP-1 receptor agonist — particularly a semaglutide-based subcutaneous injection — faces direct clearance risk from these two patents. The concentration ranges specified in the Mylan accused product (0.68 mg/mL to 2.68 mg/mL) suggest the claims may extend across common clinical dosing bands. Biosimilar developers, ANDA filers, and combination product teams should treat both patents as live obstacles until expiry or a successful IPR challenge.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map claim scope across US8129343B2 and US10335462B2, identify design-around opportunities, and surface any post-grant proceedings that may narrow enforceability. Eureka can also track the full Novo Nordisk semaglutide patent family — including continuation and divisional applications — to ensure your clearance analysis captures the complete IP perimeter, not just the two patents asserted in this action.
Run a freedom-to-operate analysis on US8129343B2 to assess your product’s exposure
Run FTO in Eureka →Similar GLP-1 and semaglutide ANDA patent cases in Delaware
Explore related Hatch-Waxman patent infringement cases involving GLP-1 receptor agonist formulations litigated in the District of Delaware.
What this case signals for the GLP-1 and semaglutide IP landscape
A 93-day settlement in a high-value Ozempic ANDA case sends clear signals to other generic entrants and brand competitors in the GLP-1 space.
Speed of settlement suggests Novo Nordisk’s patent position is formidable
When a generic challenger settles within 93 days — well before claim construction — it typically signals that the defendant’s invalidity and non-infringement arguments were not strong enough to justify protracted litigation against a blockbuster franchise. Competitors and investors should treat both asserted patents as carrying meaningful enforceability risk.
Retained court jurisdiction signals ongoing obligations worth monitoring
The court’s retention of jurisdiction to enforce the Settlement Agreement is a standard but meaningful indicator that the deal includes time-bound commercial terms — likely a future authorised entry date. Industry participants tracking generic semaglutide entry timelines should watch for subsequent FDA approval events or any future enforcement motions under this docket.
A/S v Mylan — key questions answered
Novo Nordisk asserted two patents: US8129343B2 (application US11/908834) and US10335462B2 (application US15/656042). Both patents cover semaglutide compositions and formulations underlying the Ozempic subcutaneous injection product. The accused Mylan product was a proposed generic semaglutide injection at 2 mg/3 mL (0.68 mg/mL).
The case was dismissed without prejudice pursuant to a negotiated Settlement Agreement executed by both parties. A dismissal without prejudice means no merits ruling was issued — neither patent was found valid, invalid, infringed, or not infringed. Novo Nordisk retains the right to re-file on the same patents if settlement terms are breached. The court retained jurisdiction to enforce the Settlement Agreement.
Retained jurisdiction means Judge Connolly in the District of Delaware can enforce compliance with the Settlement Agreement without requiring a new lawsuit. This is typical in Hatch-Waxman settlements where the agreement includes a future authorised launch date or licensing terms. It signals the parties have ongoing commercial obligations under the private settlement terms, though those terms are not publicly disclosed.
The case was resolved in just 93 days, filed on 1 July 2024 and closed on 2 October 2024. This is substantially faster than the typical Delaware pharmaceutical patent case, which commonly takes two to three years to reach trial. The speed suggests early settlement negotiations and a commercially motivated resolution, consistent with the high stakes of the Ozempic franchise.
Both patents remain in force with no adverse judicial finding on validity or infringement. Any company developing a semaglutide subcutaneous injection product — including biosimilar developers and ANDA filers — faces clearance risk from these patents. The concentration ranges in the accused Mylan product suggest broad formulation coverage. Companies should conduct a full FTO analysis covering the entire Novo Nordisk semaglutide patent family before advancing clinical or regulatory programmes.
PatSnap Eureka searches patents and litigation data to answer instantly.